NCT05101902View on ClinicalTrials.gov

A Study to Determine Eligibility for CAH-301 (A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) [NCT04783181])

CompletedOBSERVATIONAL
Enrollment

65

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

August 7, 2024

Study Completion Date

August 7, 2024

Conditions
Congenital Adrenal Hyperplasia
Interventions
OTHER

Pre-Screening

No intervention given

Trial Locations (1)

90094

Science37, Los Angeles

Sponsors
All Listed Sponsors
lead

Adrenas Therapeutics Inc

INDUSTRY

NCT05101902 - A Study to Determine Eligibility for CAH-301 (A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) [NCT04783181]) | Biotech Hunter | Biotech Hunter